Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer. - Wikidata - wikimedia - TriplyDB

Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer.

Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer.

http://www.wikidata.org/entity/Q37559704

about

Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET.Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.

P2860

Q36379633-E038C80C-2D87-49E4-91D1-A447528D0963 Q47769995-F5553D78-AEA8-46C8-9272-0746017F7473

P2860

Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer.

http://www.wikidata.org/entity/Q37559704

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Quantitative [18F]FMISO PET Im ...... Model of HER2+ Breast Cancer.

@en

Quantitative [18F]FMISO PET Im ...... Model of HER2+ Breast Cancer.

@nl

type

label

Quantitative [18F]FMISO PET Im ...... Model of HER2+ Breast Cancer.

@en

Quantitative [18F]FMISO PET Im ...... Model of HER2+ Breast Cancer.

@nl

prefLabel

Quantitative [18F]FMISO PET Im ...... Model of HER2+ Breast Cancer.

@en

Quantitative [18F]FMISO PET Im ...... Model of HER2+ Breast Cancer.

@nl

P1433

Q37559704-CE94FFCA-FA96-4647-A865-1C5DF78D6CF8

P1476

Q37559704-7D1B2E01-582E-43B9-BE41-8D16D5E889CB

P2093

Q37559704-42ECC236-E137-4AF5-B428-1CECBEC78FA8

Q37559704-90B42423-5813-416C-B921-A735BCBDC630

Q37559704-A8D05567-4DA9-421C-A81E-B5DCF0BC984B

Q37559704-B828D872-1493-425D-80B7-1010EC22ACD2

Q37559704-D52260E4-355A-496A-9997-83673754FE1B

Q37559704-F751682D-2C3C-4A58-B0AD-0D4447B20C8C

P2860

Q37559704-174F891D-5E99-4667-BBD9-7012AEC484C8

Q37559704-2AF1AB1B-04F8-4005-A991-D7C51CC3E2D1

Q37559704-3145F4DC-B937-42B5-977C-86F7C8F6AF31

Q37559704-3AE4A5CD-71D1-48F3-BECA-DE6451E42435

Q37559704-414C75DF-C08D-496C-9129-CD9DA6488042

Q37559704-54AB2EB9-1DED-42F4-A6B1-2A64541D595E

Q37559704-57AF6B2B-1EEF-4AC5-9FF6-B151EB524762

Q37559704-5BE3F97D-E438-45B3-98D1-75976A61DCF6

Q37559704-5D1F22B6-3F7A-453F-A321-FADD4283144B

Q37559704-7309EF63-4DF8-46E4-954A-EECE67BC95B4

P2888

Q37559704-AACC921F-A558-4402-B3E4-9B949FEBA612

P304

Q37559704-7AF194E2-97CA-488A-AB4E-D6311A0A4283

P31

Q37559704-E26EFD89-9BEF-4387-A817-09EBD79AEE15

P356

Q37559704-73B2B72C-41EE-4359-93C1-94E40362B658

P433

Q37559704-B8EA0443-B2AE-458A-BCDE-E94457909955

P478

Q37559704-09434045-D452-456F-A84A-6CE9AFEE89D0

P50

Q37559704-DC099C0F-FF24-4FDB-889A-AF00FF0C2704

P577

Q37559704-30E2EEFB-81B9-439D-843F-954327ABCA3F

P698

Q37559704-DE64C22E-7337-4E7F-84E4-C1AA6292F589

P921

Q37559704-043093D8-7A02-42A7-B055-74A1AB02EAD7

P932

Q37559704-24725D2B-5FC1-4C8C-8390-C1B47925C201

P356

S11307-016-0994-1

P1433

Molecular Imaging and Biology

P1476

Quantitative [18F]FMISO PET Im ...... Model of HER2+ Breast Cancer.

@en

P2093

Anna G Sorace

http://www.w3.org/2001/XMLSchema#string

Anum K Syed

http://www.w3.org/2001/XMLSchema#string

C Chad Quarles

http://www.w3.org/2001/XMLSchema#string

Hakmook Kang

http://www.w3.org/2001/XMLSchema#string

Stephanie L Barnes

http://www.w3.org/2001/XMLSchema#string

Violeta Sanchez

http://www.w3.org/2001/XMLSchema#string

P2860

Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?

Normalization of the vasculature for treatment of cancer and other diseases.

18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer

18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.

Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions.

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy

Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma

Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.

P2888

s11307-016-0994-1

P304

130-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11307-016-0994-1

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Thomas E Yankeelov

P577

2016-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27506906

http://www.w3.org/2001/XMLSchema#string

P921

P932

5214951

http://www.w3.org/2001/XMLSchema#string